CD22
B-cell antigen targeted by inotuzumab ozogamicin (ADC) and emerging CD22 CAR-T therapies.
No Clinical Trials found for this biomarker.
B-cell antigen targeted by inotuzumab ozogamicin (ADC) and emerging CD22 CAR-T therapies.
No Clinical Trials found for this biomarker.